CoChat

Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review

Open access
Sørensen, Anders, Juhl Jørgensen, Karsten, Munkholm, Klaus · 2022 · Therapeutic Advances in Psychopharmacology

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index; 18 of the 60 sources its claims cite were checked for support.

Abstract

Background: Tapering and discontinuing antidepressants are important aspects of the management of patients with depression and should therefore be considered in clinical practice guidelines. Objectives: We aimed to assess the extent and content, and appraise the quality, of guidance on tapering and discontinuing antidepressants in major clinical practice guidelines on depression. Methods: Systematic review of clinical practice guidelines on depression issued by national health authorities and major national or international professional organisations in the United Kingdom, the United States, Canada, Australia, Singapore, Ireland and New Zealand (PROSPERO CRD42020220682). We searched PubMed, 14 guideline registries and the websites of relevant organisations (last search 25 May 2021). The clinical practice guidelines were assessed for recommendations and information relevant to tapering and discontinuing antidepressants. The quality of the clinical practice guidelines as they pertained to tapering and discontinuation was assessed using the AGREE II tool. Results: Of the 21 included clinical practice guidelines, 15 (71%) recommended that antidepressants are tapered gradually or slowly, but none provided guidance on dose reductions, how to distinguish withdrawal symptoms from relapse or how to manage withdrawal symptoms. Psychological challenges were not addressed in any clinical practice guideline, and the treatment algorithms and flow charts did not include discontinuation. The quality of the clinical practice guidelines was overall low. Conclusion: Current major clinical practice guidelines provide little support for clinicians wishing to help patients discontinue or taper antidepressants in terms of mitigating and managing withdrawal symptoms. Patients who have deteriorated upon following current guidance on tapering and discontinuing antidepressants thus cannot be concluded to have experienced a relapse. Better guidance requires better randomised trials investigating interventions for discontinuing or tapering antidepressants.

Overview

CoChat Summary

TL;DR

This systematic review of 21 major depression clinical practice guidelines found that most recommend gradual or slow antidepressant tapering, but provide little concrete guidance on dose reduction, withdrawal management, or distinguishing withdrawal from relapse. Guideline quality on tapering and discontinuation was overall low, and the authors conclude better guidance requires better randomised trials.

Key findings

  • Of 21 included guidelines, 15 (71%) recommended gradual or slow tapering, but none recommended hyperbolic tapering (0%); only 2 (10%) alluded to a specific dose-reduction regimen.
  • Withdrawal symptoms were mentioned as a possible harm in 15 (71%) guidelines and relapse/recurrence in 14 (67%), but only 4 (19%) noted the symptomatic overlap or risk of misinterpreting withdrawal as relapse.
  • Psychological challenges, potential benefits of coming off antidepressants, and peer-support measures were not mentioned in any guideline (0% each).
  • AGREE II overall quality scores for tapering/discontinuation guidance ranged from 8% to 33% (mean 17%, SD 8%), and no guideline reached the predefined >70% threshold for high quality.

Methods

  • Systematic review of clinical practice guidelines on depression issued by national health authorities and major national or international professional organisations in the UK, US, Canada, Australia, Singapore, Ireland, and New Zealand (PROSPERO CRD42020220682).
  • Searched PubMed, 14 guideline registries, relevant organisation websites, Google top 100 hits, and reference lists; last search 25 May 2021. Included 21 unique guidelines (reported in 26 records), published 1998–2020.
  • Two researchers independently extracted data on tapering/discontinuation guidance and assessed quality using AGREE II, focusing items specifically on tapering and discontinuation; results were summarised as proportions and mean domain scores.

Limitations

  • Stated by the authors: only English-language guidelines were included, so guidelines from non-English-speaking countries may have been missed; AGREE II has no validated high/low quality threshold and the cutoff used may be considered conservative; categorisation and quality appraisal involved subjective judgements.
  • Evident from the text: the AGREE II appraisal was specific to tapering and discontinuation issues rather than an assessment of the guidelines in their totality, and the review evaluates guideline content rather than patient outcomes from tapering interventions.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1177/20451253211067656

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Flowchart of study selection process.
Figure 1. Flowchart of study selection process.CC BY-NC · PubMed Central
Figure 2. Prevalence of guidance on tapering in clinical practice guidelines on depression. mADM, maintenance antidepressant medication.
Figure 2. Prevalence of guidance on tapering in clinical practice guidelines on depression. mADM, maintenance antidepressant medication.CC BY-NC · PubMed Central

Verification

Claims the paper makes

10 Valid · 0 Not valid · 19 Not checked · 77 Own results and interpretations

69 more claims · 4 with their cited sources checked

Create a free account to see all 106 claims and to verify the 42 references still open.

See all claims — free account
  • Probably not a substantial claim. 26
  • It may state two separate claims as one. 13

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

3 of 3

Citations

Cites

Show all 44 references

Research works printed but not linked: 3

  1. Van Leeuwen E, 2021, Cochrane Database Syst Rev, 4
  2. American Psychological Association (APA), 2019, Clinical practice guideline for the treatment of depression across three cohorts
  3. National Institute for Health and Care Excellence (NICE), 2012, Depression: evidence update April 2012: a summary of selected new evidence relevant to NICE clinical guideline 90 ‘The treatment and management of depression in adults’ (2009)

Cited by

See all 52

Metadata

Authors
Sørensen, A., Juhl Jørgensen, K., & Munkholm, K.
Affiliations
  • Copenhagen University Hospital (DK)
  • Centre for Evidence-Based Medicine Odense (CEBMO) and Cochrane Denmark, Department of Clinical Research, University of Southern Denmark, Odense, Denmark
  • University of Southern Denmark (DK)
Corresponding author
Sørensen, Anders
Venue
Therapeutic Advances in Psychopharmacology
Published
2022-01
Volume
12
Pages
20451253211067656-20451253211067656
ISSN
  • 2045-1253 (ISSN-L)
  • 2045-1261
OpenAlex
W4211248784
Cited by
52
References
44
Citations by year
2026: 9 · 2025: 19 · 2024: 9 · 2023: 11 · 2022: 4
FWCI
1.54
Type
journal article
Language
en
Open access
Locations
  • Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • University of Southern Denmark Research Portal (University of Southern Denmark) (publishedVersion, cc-by-nc)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Research at the University of Copenhagen (University of Copenhagen) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
Keywords
antidepressant tapering, antidepressant discontinuation, depression, guideline quality, antidepressant withdrawal symptoms, relapse, dose reduction, treatment algorithm

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review. https://app.cochat.ai/papers/10.1177/20451253211067656
The paper
Sørensen, A., Juhl Jørgensen, K., & Munkholm, K. (2022). Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/20451253211067656

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.